-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a message published on the website of the State Food and Drug Administration showed that the registration application for the implantable left ventricular assist system, an innovative product produced by Suzhou Tongxin Medical Devices Co.
, Ltd.
, was approved
.
, Ltd.
, was approved
.
For a long time, the treatment of heart failure has been a major challenge for global medicine, especially for the treatment of advanced heart failure.
Existing drugs and heart rate control devices are difficult to reverse the progression of the disease, and human heart transplantation is limited by the source of donors.
Benefit more patients
.
Artificial hearts provide more options for patients with advanced heart failure
.
Existing drugs and heart rate control devices are difficult to reverse the progression of the disease, and human heart transplantation is limited by the source of donors.
Benefit more patients
.
Artificial hearts provide more options for patients with advanced heart failure
.
The core technology of the approved implantable left ventricular assist system is mainly full magnetic levitation blood pump technology.
It has obtained a number of patents in China and the United States, and is the first domestic medical device
.
Compared with similar international products, the key performance indicators of this product have reached the same level, the size of the blood pump is smaller, and the implantation is more aggressive.
It can meet the clinical needs of China in the field of heart failure surgical device treatment and has important social benefits.
.
It has obtained a number of patents in China and the United States, and is the first domestic medical device
.
Compared with similar international products, the key performance indicators of this product have reached the same level, the size of the blood pump is smaller, and the implantation is more aggressive.
It can meet the clinical needs of China in the field of heart failure surgical device treatment and has important social benefits.
.
It is understood that the implantable left ventricular assist system consists of a blood pump, an external controller, a rechargeable lithium battery, an adapter, a battery charger, a communication isolation module, a monitor, surgical tools, and a shower bag
.
Used in conjunction with specific artificial blood vessels, it provides mechanical support for blood circulation in patients with advanced refractory left heart failure, and is used for transitional treatment before heart transplantation or restoring heart function
.
.
Used in conjunction with specific artificial blood vessels, it provides mechanical support for blood circulation in patients with advanced refractory left heart failure, and is used for transitional treatment before heart transplantation or restoring heart function
.
So far, the State Food and Drug Administration has approved 131 innovative medical device products to go on the market
.
(Yan Ruoyu)
.
(Yan Ruoyu)
Recently, a message published on the website of the State Food and Drug Administration showed that the registration application for the implantable left ventricular assist system, an innovative product produced by Suzhou Tongxin Medical Devices Co.
, Ltd.
, was approved
.
, Ltd.
, was approved
.
For a long time, the treatment of heart failure has been a major challenge for global medicine, especially for the treatment of advanced heart failure.
Existing drugs and heart rate control devices are difficult to reverse the progression of the disease, and human heart transplantation is limited by the source of donors.
Benefit more patients
.
Artificial hearts provide more options for patients with advanced heart failure
.
Existing drugs and heart rate control devices are difficult to reverse the progression of the disease, and human heart transplantation is limited by the source of donors.
Benefit more patients
.
Artificial hearts provide more options for patients with advanced heart failure
.
The core technology of the approved implantable left ventricular assist system is mainly full magnetic levitation blood pump technology.
It has obtained a number of patents in China and the United States, and is the first domestic medical device
.
Compared with similar international products, the key performance indicators of this product have reached the same level, the size of the blood pump is smaller, and the implantation is more aggressive.
It can meet the clinical needs of China in the field of heart failure surgical device treatment and has important social benefits.
.
It has obtained a number of patents in China and the United States, and is the first domestic medical device
.
Compared with similar international products, the key performance indicators of this product have reached the same level, the size of the blood pump is smaller, and the implantation is more aggressive.
It can meet the clinical needs of China in the field of heart failure surgical device treatment and has important social benefits.
.
It is understood that the implantable left ventricular assist system consists of a blood pump, an external controller, a rechargeable lithium battery, an adapter, a battery charger, a communication isolation module, a monitor, surgical tools, and a shower bag
.
Used in conjunction with specific artificial blood vessels, it provides mechanical support for blood circulation in patients with advanced refractory left heart failure, and is used for transitional treatment before heart transplantation or restoring heart function
.
.
Used in conjunction with specific artificial blood vessels, it provides mechanical support for blood circulation in patients with advanced refractory left heart failure, and is used for transitional treatment before heart transplantation or restoring heart function
.
So far, the State Food and Drug Administration has approved 131 innovative medical device products to go on the market
.
(Yan Ruoyu)
.
(Yan Ruoyu)
Recently, a message published on the website of the State Food and Drug Administration showed that the registration application for the implantable left ventricular assist system, an innovative product produced by Suzhou Tongxin Medical Devices Co.
, Ltd.
, was approved
.
, Ltd.
, was approved
.
For a long time, the treatment of heart failure has been a major challenge for global medicine, especially for the treatment of advanced heart failure.
Existing drugs and heart rate control devices are difficult to reverse the progression of the disease, and human heart transplantation is limited by the source of donors.
Benefit more patients
.
Artificial hearts provide more options for patients with advanced heart failure
.
Existing drugs and heart rate control devices are difficult to reverse the progression of the disease, and human heart transplantation is limited by the source of donors.
Benefit more patients
.
Artificial hearts provide more options for patients with advanced heart failure
.
The core technology of the approved implantable left ventricular assist system is mainly full magnetic levitation blood pump technology.
It has obtained a number of patents in China and the United States, and is the first domestic medical device
.
Compared with similar international products, the key performance indicators of this product have reached the same level, the size of the blood pump is smaller, and the implantation is more aggressive.
It can meet the clinical needs of China in the field of heart failure surgical device treatment and has important social benefits.
.
Medical equipment medical equipment medical equipmentIt has obtained a number of patents in China and the United States, and is the first domestic medical device
.
Compared with similar international products, the key performance indicators of this product have reached the same level, the size of the blood pump is smaller, and the implantation is more aggressive.
It can meet the clinical needs of China in the field of heart failure surgical device treatment and has important social benefits.
.
It is understood that the implantable left ventricular assist system consists of a blood pump, an external controller, a rechargeable lithium battery, an adapter, a battery charger, a communication isolation module, a monitor, surgical tools, and a shower bag
.
Used in conjunction with specific artificial blood vessels, it provides mechanical support for blood circulation in patients with advanced refractory left heart failure, and is used for transitional treatment before heart transplantation or restoring heart function
.
Heart, heart, heart.
Used in conjunction with specific artificial blood vessels, it provides mechanical support for blood circulation in patients with advanced refractory left heart failure, and is used for transitional treatment before heart transplantation or restoring heart function
.
So far, the State Food and Drug Administration has approved 131 innovative medical device products to go on the market
.
(Yan Ruoyu)
.
(Yan Ruoyu)
